Back
Relmada Therapeutics, Inc. Stock Predictions
Missed $0.81? RAD Intel Now Open at $0.85/Share
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
32
RLMD
Relmada Therapeutics, Inc.
Last Price:
$3.99
Seasonality Move:
6.46%
7 Day Trial
ALL ACCESS PASS
$
7
This AI Layer Just Raised Its Share Price
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiRelmada Therapeutics, Inc. Stock Forecast
-
Is Relmada Therapeutics, Inc. Stock Undervalued?The current Relmada Therapeutics, Inc. [RLMD] share price is $4.00. The Score for RLMD is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.
-
RLMD is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
Will Relmada Therapeutics, Inc. Stock Go Up Next Year?
Data Unavailable
Relmada Therapeutics, Inc. Stock Rating
Data Unavailable
Relmada Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
relmada.com
52-Week Data
52-Week High:
5.12
52-Week Low:
0.24
Prediction Charts
Market Cap:
293.3M
Price in USD:
4.00
Volume:
878.5K
Beta:
0.58
Technical Analysis
SMA50:
2.87
SMA100:
1.91
SMA200:
1.19
52-Wk Change:
534.92%
Stock Predictions
-
Is Relmada Therapeutics, Inc. stock public?Yes, Relmada Therapeutics, Inc. is a publicly traded company.
-
What is the Relmada Therapeutics, Inc. stock quote today?The Relmada Therapeutics, Inc. stock price is 4.00 USD today.
-
How to buy Relmada Therapeutics, Inc. stock online?You can buy Relmada Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-14 | 3.54 | 3.95 | 4.34 | 3.31 |
| Nov-17 | 3.93 | 3.97 | 4.32 | 3.90 |
| Nov-18 | 3.94 | 4.27 | 4.39 | 3.72 |
| Nov-19 | 4.50 | 4.18 | 5.12 | 4.07 |
| Nov-20 | 4.27 | 4.32 | 4.55 | 4.14 |
| Nov-21 | 4.30 | 4.27 | 4.37 | 3.81 |
| Nov-24 | 4.27 | 4.30 | 4.35 | 4.05 |
| Nov-25 | 4.37 | 4.26 | 4.38 | 3.99 |
| Nov-26 | 4.30 | 4.19 | 4.30 | 3.86 |
| Nov-28 | 4.19 | 4.51 | 4.56 | 4.15 |
| Dec-1 | 4.50 | 4.42 | 4.50 | 3.95 |
| Dec-2 | 4.39 | 4.04 | 4.46 | 3.93 |
| Dec-3 | 4.05 | 4.06 | 4.25 | 3.70 |
| Dec-4 | 4.04 | 4.00 | 4.07 | 3.83 |
Relmada Therapeutics, Inc. Earnings
Data Unavailable
Relmada Therapeutics, Inc. Forecast Revenue Growth
Data Unavailable
-
Analysts estimate an earnings increase this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.89 per share, and an increase next year of $0.47 per share.
* Relmada Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.